Dijon, France April 2, 2024, 10:30am CET — Crossject , a specialty pharma company developing needle-free auto-injectors for emergency situations, announces progress on multiple fronts in its clinical development, registration and U.S. commercial strategy and reports its financial results for the year ending December 31, 2023.Crossject is approaching a number of important value inflection points, which have the potential to transform our company and deliver substantial shareholder value.
In parallel, we expect to file in H1 2025 for an NDA of ZEPIZURE®. We are firmly focused on the final development stages for epileptic crises, including an upcoming 505 pivotal bioequivalence study, as part of the NDA that we anticipate to file in H1 2025. We are also working on activities related to its registration and pre-commercialization in the United States, since Crossject intends to retain U.S. commercial rights to ZEPIZURE®.
Our two main additional programs, ZENEO® Hydrocortisone and ZENEO® Adrenaline, are also progressing toward planned market authorization filings in 2025 and 2026 respectively. Philippe Monnot, CEO and one of the founders of Gemmes Venture, our reference shareholder, has confirmed his support : In 2023, we accelerated our research and development and overall activities. As a result, we recorded a very substantial increase in operating income to €12.8 million, an increase of 32% over 2022.The Operating expenses increased by 9% in 2023 over 2022, a very moderate rise in relation to the increase of our operating income.
We reported an Operating loss of €12.3 million, compared with a loss of €13.3 million in 2022 with the relative stability reflecting our increased operating expenses and their partial offsetting by operating income.